Full history for every metric is available with a Kvantra account
Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1,449 | 1,580 | 1,853 | 2,082 | 2,342 | 2,618 | 2,705 | 2,792 |
| Operating profit | €m | 720 | 824 | ||||||
| Net profit | €m | 355 | 386 | 312 | 389 | 417 | 444 | 497 | 664 |
| EPS reported | € | 2.12 | 2.38 | ||||||
| Operating cashflow per share | € | 2.90 | 3.17 | ||||||
| Capex per share | € | 0.41 | 0.31 | ||||||
| FCF per share | € | 2.49 | 2.86 | ||||||
| Free cash flow | €m | 512 | 582 | ||||||
| Net debt | €m | 2,001 | 1,919 | ||||||
| Book value equity | €m | 1,920 | 2,131 | ||||||
| Book value per share | € | 9.18 | 10.23 | ||||||
| Number of shares | m | 209.16 | 208.24 | ||||||
| DPS (TTM paid) | € | 1.34 | 1.34 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 22.90 | 22.27 | ||||||
| P/B LTM | x | 5.20 | 5.02 | ||||||
| P/S LTM | x | 3.81 | 3.96 | ||||||
| P/FCF LTM | x | 19.49 | 18.39 | ||||||
| EV/EBITDA LTM | x | 13.54 | 12.74 | ||||||
| EV/Sales LTM | x | 4.59 | 4.67 | ||||||
| Earnings Yield LTM | % | 4.37% | 4.49% | ||||||
| FCF Yield | % | 5.13% | 5.44% | ||||||
| Quality | |||||||||
| ROE | % | 23.11% | 24.74% | ||||||
| ROIC | % | 12.11% | 13.55% | ||||||
| Operating margin | % | 27.49% | 30.46% | ||||||
| Gross margin | % | 68.27% | 70.74% | ||||||
| FCF/Sales | % | 19.55% | 21.51% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +6.53% | +22.05% | ||||||
| Sales Growth YoY | % | +11.82% | +9.10% | ||||||
| Net Income Growth YoY | % | +6.51% | +22.08% | ||||||
| FCF Growth | % | -4.36% | +16.32% | ||||||
| Operating Profit Growth | % | +12.65% | +30.53% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.68% | 2.53% | ||||||
| Dividend Growth | % | +5.51% | +5.51% | ||||||
| Payout Ratio | % | 60.34% | 54.94% | ||||||
| FCF/Debt | x | 0.21 | 0.25 | ||||||
| Net Debt/EBITDA | x | 2.30 | 1.94 | ||||||
| EBIT/Net interest | x | 7.25 | 8.13 | ||||||
| Net debt/market cap | % | 20.06% | 17.93% | ||||||
| Net debt/Equity | x | 1.04 | 0.90 | ||||||
| Gross debt/equity | x | 1.29 | 1.08 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
Based on consensus from external analysts. Not Kvantra's opinion.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free